Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/16/2025

Bladder Relaxing Medications for Overactive Bladder

First-Line Treatment: Behavioral Therapy

  • The American Urological Association recommends that all patients with overactive bladder should receive behavioral therapies as first-line treatment before starting any bladder relaxing medications 1
  • Behavioral treatments, such as bladder training, pelvic floor muscle exercises, and fluid management, are as effective as antimuscarinic medications for reducing symptoms and are risk-free 1
  • These interventions significantly reduce incontinence episodes, frequency, nocturia, and improve quality of life 1
  • Weight loss of just 8% in obese women reduced urgency incontinence episodes by 42% 1
  • A 25% reduction in fluid intake and caffeine reduction both significantly decreased frequency and urgency 1

Second-Line Treatment: Oral Antimuscarinic Medications

  • The American Urological Association recommends that oral antimuscarinic agents should be offered as second-line pharmacologic therapy when behavioral therapy alone is insufficient 1
  • No compelling evidence exists for differential efficacy across antimuscarinic medications, such as darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, and trospium 1
  • All antimuscarinic medications reduce symptoms but commonly cause non-life-threatening side effects, including dry mouth, constipation, dry eyes, blurred vision, dyspepsia, UTI, urinary retention, and impaired cognitive function 1
  • Patients with more severe baseline symptoms experience greater absolute symptom reductions 1

Alternative Second-Line Treatment: β3-Adrenoceptor Agonist

  • The European Association of Urology recommends mirabegron, a β3-adrenoceptor agonist, as an effective alternative second-line option, particularly for patients concerned about antimuscarinic side effects 2
  • Mirabegron demonstrates fewer anticholinergic side effects, such as dry mouth, constipation, or cognitive impairment, compared to antimuscarinics 5
  • Mirabegron has better adherence rates compared to antimuscarinics 2
  • Mirabegron is effective in both men and women with overactive bladder 2

Combination Therapy for Refractory Symptoms

  • The American Urological Association recommends combination therapy with mirabegron plus an antimuscarinic agent, particularly solifenacin, for patients with inadequate response to monotherapy 3
  • Combination therapy demonstrates superior reduction in urinary incontinence episodes, micturitions, urgency episodes, and nocturia compared to either monotherapy 4

Critical Contraindications and Precautions

  • The American Urological Association recommends that antimuscarinics are contraindicated in patients with narrow-angle glaucoma, unless approved by a treating ophthalmologist, and in patients using solid oral forms of potassium chloride 1
  • Antimuscarinics should be used with extreme caution in patients with impaired gastric emptying, history of urinary retention, and men with bladder outlet obstruction 1
  • Mirabegron should be administered with caution when combined with antimuscarinic medications due to increased risk of urinary retention, especially in patients with bladder outlet obstruction 3

Monitoring During Treatment

  • The American Urological Association recommends monitoring for urinary retention, cognitive function, and anticholinergic side effects in patients receiving antimuscarinic therapy 1
  • Regular blood pressure monitoring is recommended for patients receiving mirabegron therapy, especially initially and in hypertensive patients 3
  • Discontinue mirabegron if worsening voiding symptoms or urinary stream occurs 3

REFERENCES

3

Mirabegron for Overactive Bladder Treatment [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

4

Mirabegron 25mg for Overactive Bladder Treatment [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

5

Mirabegron Treatment Guidelines for Overactive Bladder [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025